272 related articles for article (PubMed ID: 27983753)
1. Effectiveness and Safety of Tigecycline Compared with Other Broad-Spectrum Antimicrobials in Abdominal Solid Organ Transplant Recipients with Polymicrobial Intraabdominal Infections.
Liebenstein T; Schulz LT; Viesselmann C; Bingen E; Musuuza J; Safdar N; Rose WE
Pharmacotherapy; 2017 Feb; 37(2):151-158. PubMed ID: 27983753
[TBL] [Abstract][Full Text] [Related]
2. Clinical response and mortality in tigecycline complicated intra-abdominal infection and complicated skin and soft-tissue infection trials.
Bassetti M; McGovern PC; Wenisch C; Meyer RD; Yan JL; Wible M; Rottinghaus ST; Quintana A
Int J Antimicrob Agents; 2015 Sep; 46(3):346-50. PubMed ID: 26155003
[TBL] [Abstract][Full Text] [Related]
3. Safety and tolerability of tigecycline for the treatment of complicated skin and soft-tissue and intra-abdominal infections: an analysis based on five European observational studies.
Guirao X; Sánchez García M; Bassetti M; Bodmann KF; Dupont H; Montravers P; Heizmann WR; Capparella MR; Simoneau D; Eckmann C
J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii37-44. PubMed ID: 23772045
[TBL] [Abstract][Full Text] [Related]
4. Therapy of 1,025 severely ill patients with complicated infections in a German multicenter study: safety profile and efficacy of tigecycline in different treatment modalities.
Bodmann KF; Heizmann WR; von Eiff C; Petrik C; Löschmann PA; Eckmann C
Chemotherapy; 2012; 58(4):282-94. PubMed ID: 23052187
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy of tigecycline used as monotherapy or in combination regimens for complicated infections with documented involvement of multiresistant bacteria.
Heizmann WR; Löschmann PA; Eckmann C; von Eiff C; Bodmann KF; Petrik C
Infection; 2015 Feb; 43(1):37-43. PubMed ID: 25367409
[TBL] [Abstract][Full Text] [Related]
6. Tigecycline use in cancer patients with serious infections: a report on 110 cases from a single institution.
Chemaly RF; Hanmod SS; Jiang Y; Rathod DB; Mulanovich V; Adachi JA; Rolston KV; Raad II; Hachem RY
Medicine (Baltimore); 2009 Jul; 88(4):211-220. PubMed ID: 19593226
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of tigecycline for the treatment of complicated intra-abdominal infections in real-life clinical practice from five European observational studies.
Eckmann C; Montravers P; Bassetti M; Bodmann KF; Heizmann WR; Sánchez García M; Guirao X; Capparella MR; Simoneau D; Dupont H
J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii25-35. PubMed ID: 23772043
[TBL] [Abstract][Full Text] [Related]
8. Use of intravenous tigecycline in patients with severe Clostridium difficile infection: a retrospective observational cohort study.
Gergely Szabo B; Kadar B; Szidonia Lenart K; Dezsenyi B; Kunovszki P; Fried K; Kamotsay K; Nikolova R; Prinz G
Clin Microbiol Infect; 2016 Dec; 22(12):990-995. PubMed ID: 27599690
[TBL] [Abstract][Full Text] [Related]
9. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744].
Oliva ME; Rekha A; Yellin A; Pasternak J; Campos M; Rose GM; Babinchak T; Ellis-Grosse EJ; Loh E;
BMC Infect Dis; 2005 Oct; 5():88. PubMed ID: 16236177
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of tigecycline versus ceftriaxone plus metronidazole for the treatment of complicated intra-abdominal infections: results from a randomized, controlled trial.
Qvist N; Warren B; Leister-Tebbe H; Zito ET; Pedersen R; McGovern PC; Babinchak T
Surg Infect (Larchmt); 2012 Apr; 13(2):102-9. PubMed ID: 22439781
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, safety, and tolerability of antimicrobial agents for complicated intra-abdominal infection: a systematic review and network meta-analysis.
Kong W; Deng T; Li S; Shu Y; Wu Y
BMC Infect Dis; 2023 Apr; 23(1):256. PubMed ID: 37085768
[TBL] [Abstract][Full Text] [Related]
12. Resistance mechanisms and epidemiology of multiresistant pathogens in Europe and efficacy of tigecycline in observational studies.
Heizmann WR; Dupont H; Montravers P; Guirao X; Eckmann C; Bassetti M; García MS; Capparella MR; Simoneau D; Bodmann KF
J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii45-55. PubMed ID: 23772046
[TBL] [Abstract][Full Text] [Related]
13. Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI).
Solomkin J; Hershberger E; Miller B; Popejoy M; Friedland I; Steenbergen J; Yoon M; Collins S; Yuan G; Barie PS; Eckmann C
Clin Infect Dis; 2015 May; 60(10):1462-71. PubMed ID: 25670823
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial.
Sacchidanand S; Penn RL; Embil JM; Campos ME; Curcio D; Ellis-Grosse E; Loh E; Rose G
Int J Infect Dis; 2005 Sep; 9(5):251-61. PubMed ID: 16099700
[TBL] [Abstract][Full Text] [Related]
15. A practice-based observational study identifying factors associated with the use of high-dose tigecycline in the treatment of secondary peritonitis in severely ill patients.
Maseda E; Suárez-de-la-Rica A; Anillo V; Salgado P; Tamayo E; García-Bernedo CA; Ramasco F; Villagrán MJ; López-Tofiño A; Giménez MJ; Granizo JJ; Hernández-Gancedo C; Aguilar L; Gilsanz F
Rev Esp Quimioter; 2015 Feb; 28(1):47-53. PubMed ID: 25690145
[TBL] [Abstract][Full Text] [Related]
16. Prescription behaviours for tigecycline in real-life clinical practice from five European observational studies.
Bassetti M; Eckmann C; Bodmann KF; Dupont H; Heizmann WR; Montravers P; Guirao X; Capparella MR; Simoneau D; Sánchez García M
J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii5-14. PubMed ID: 23772047
[TBL] [Abstract][Full Text] [Related]
17. Tigecycline: a novel broad-spectrum antimicrobial.
Slover CM; Rodvold KA; Danziger LH
Ann Pharmacother; 2007 Jun; 41(6):965-72. PubMed ID: 17519296
[TBL] [Abstract][Full Text] [Related]
18. The Retrospective Cohort of Extended-Infusion Piperacillin-Tazobactam (RECEIPT) study: a multicenter study.
Yost RJ; Cappelletty DM;
Pharmacotherapy; 2011 Aug; 31(8):767-75. PubMed ID: 21923603
[TBL] [Abstract][Full Text] [Related]
19. An essential requirement for the licensing of new antibiotics is the provision of data on efficacy and safety obtained from clinical trials in which patients are randomized to receive either the experimental drug or a comparator antibiotic regarded as a standard treatment option. Preface.
Johnson AP; Leibovici L
J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii1. PubMed ID: 23930279
[No Abstract] [Full Text] [Related]
20. Tigecycline: an update.
Stein GE; Babinchak T
Diagn Microbiol Infect Dis; 2013 Apr; 75(4):331-6. PubMed ID: 23357291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
